ESMO Open Podcast
Health & Wellness Podcasts >
Epigenetic Biomarkers in Cancer
Epigenetic biomarkers are emerging across tumor types in cancer research. Aberrant DNA methylation in tumors results in silencing of distinct genes. This modification is very stable and therefore can reliably be assessed and used as a diagnostic but also prognostic biomarker. Recently, DNA methylation was validated as an additional diagnostic biomarker in brain tumors. Here, the methylation profile allowed precise clinical diagnosis associated with the survival prognosis. Therefore, the...
Questions asked in everyday practice: Immune Checkpoint Inhibitors
Immunotherapy has been approved for several indications in Oncology, resulting in an increasing number of physicians that use it to treat their patients. In this podcast, Teresa Amaral, member of the ESMO YOC, interviews Professor John Haanen (Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology; Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, the Netherlands) on the topic: “Questions asked in everyday practice:...
New therapeutic anti-CEA anti-CD3 bispecific antibody in colorectal cancer
Colorectal cancer has a strong interaction with the immune system as underlined by the high prognostic impact of tumor infiltrating lymphocytes in the tumor core as well as the infiltration margin in the localized setting. However in the metastatic scenario the vast majority of these tumors - the 95% lacking deficiencies in the missmatch repair sustem- demonstrated to be immune-elusive. The new therapeutic bispecific anti-CEA anti CD3 antidobody CEA-TCB is therefore a new, promising immune...
New therapeutic targets in the inflammatory microenvironment
In this podcast, Editor Anna Berghoff speaks to Professor Eric Tartour (Department of Immunology; Hôpital Européen Georges Pompidou) about new therapeutic targets in the inflammatory microenvironment. The introduction of immune checkpoint inhibitors introduced a new era of oncology. The CTLA4 or PD1/PDL1 axis targeting immune checkpoint inhibitors have shown remarkable and long lasting responses in a variety of tumor types, Here, the biology of immune checkpoint inhibitors is outlined...
Heterogeneity of colon cancer: from bench to bedside
Professor Marco Merlano, Oncology Department Santa Croce e Carle, General Hospital, Italy, is the leading author of the ESMO Open article ‘Heterogeneity of colon cancer: from bench to bedside’, summarised in this podcast. Abstract The large bowel shows biomolecular, anatomical and bacterial changes that proceed from the proximal to the distal tract. These changes account for the different behaviour of colon cancers arising from the diverse sides of the colon–rectum as well as for the...
New horizon in breast cancer therapy - ESMO congress, ASCO and San Antonio Symposium’s highlights
Elżbieta Senkus, Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdańsk, Poland, (email@example.com) presents an overview of new therapies on the horizon for breast cancer in terms of data presented at the ESMO Congress, ASCO, and the San Antonio Breast Cancer Symposium. In the adjuvant setting, results from the MINDACT trial, which evaluated genomic versus clinical assessment for risk stratification, are described. Data on the role of anthracyclines in adjuvant...
ASCO Highlights podcast: Head and neck cancers
These highlights are presented by Marco Merlano, Department of Medical Oncology, Santa Croce General Hospital, Cuneo, Italy,(firstname.lastname@example.org). A critical review of the head and neck cancer research highlights of the American Society of Clinical Oncology (ASCO) meeting 2016, held in June 2016 in Chicago, is presented in this podcast. Considering the most interesting and practice-changing trials reported at the meeting, the key trial comparing gemcitabine plus cisplatin against 5-FU plus...
The Cancer Genome - Highlights of a Nature Medicine Perspective
These highlights are presented by Emile Voest, The Netherlands Cancer Institute - Molecular Oncology, Amsterdam, Netherlands (email@example.com). The author reviews the recently published article “Facilitating a Culture of Responsible and Effective Sharing of Cancer Genome Data” (Nat Med. 2016 May 5;22(5):464-71 - http://goo.gl/O3DRMf.) considering why data sharing is important and explaining the obstacles and problems involved. The need to identify common bioinformatics pipelines and resolve...
Highlights from the ESMO Symposium on Signalling Pathways in Cancer 2016
A critical review of the highlights of the ESMO Symposium on Signalling Pathways in Cancer 2016, held March 2016 in partnership with the European Association of Cancer Research, is presented in this podcast. The meeting addressed developments in personalized medicine associated with the HER/EGFR family. Key subjects discussed were the bases of the mechanisms of signal transduction and primary and secondary resistance to EGFR-inhibiting drugs, and the emergence of better characterized...